Alcon acquires Tear Film Innovations
Tear Film's iLux Device offers innovative, customizable treatment for Meibomian Gland Dysfunction, a leading cause of dry eye.
Alcon has acquired Tear Film Innovations, a privately-held company and manufacturer of the iLux Device, an innovative therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye.
Handheld and portable, the iLux Device enables eye care professionals to directly target a patient's blocked meibomian glands and provide therapy through an in-office treatment. Using the iLux Device, a practitioner can warm the eyelids via disposable silicone pads to address blocked meibomian glands through the application of light-based heating. While applying the iLux Device, the practitioner can view the eyelid margin and apply manually-controlled compression to express blockages, making adjustments as needed to tailor treatment to the individual needs of the patient. Most treatments can be completed in a matter of minutes.
The Tear Film acquisition expands Alcon's leading portfolio of ocular health products, including several leading treatments for the temporary relief of dry eye symptoms.
"With the acquisition of Tear Film, we're excited to bring this latest innovation to treat the millions of people around the world who suffer from dry eye," said Andy Pawson, Alcon President & General Manager, Global Vision Care Franchise. "Alcon remains committed to improving the lives of patients around the world through innovative technologies like the iLux Device to address significant unmet needs in eye care."
The iLux Device received 510(k) clearance from the FDA in December 2017, and was officially launched by Tear Film in May 2018 at the annual meeting of the American Society for Cataract and Refractive Surgery.
"Since launching the iLux Device earlier this year, we've seen an enthusiastic response from eye care professionals who have already begun to incorporate it as an advanced treatment option for patients suffering from Meibomian Gland Dysfunction," said Rob Thornhill, CEO of Tear Film. "Now, as part of Alcon, we're eager to bring this technology to even more offices throughout the world."
The iLux Device is currently available in the US and Canada. Alcon expects to announce plans to expand to other countries in 2019.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.